Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase TRIM4 (TRIM4) is a cytoplasmic enzyme belonging to the tripartite motif (TRIM) family of proteins, defined by its RING domain, two B-box domains, and a coiled-coil region[3]. TRIM4 acts as an E3 ubiquitin ligase, mediating the transfer of ubiquitin to specific substrate proteins, particularly influencing immune signaling pathways such as the RIG-I-dependent antiviral response through K63-linked ubiquitination of CARD domain-containing substrates[1][3]. TRIM4 has been associated with regulation of mitochondrial organization, cellular response to oxidative stress, and promotion of cell death under certain conditions[2]. Its expression is implicated in cancer biology, especially as a prognostic biomarker in hepatocellular carcinoma where decreased TRIM4 expression correlates with worse prognosis and higher recurrence risk[2]. No approved drugs directly targeting TRIM4 are currently known, and there are no specific safety concerns reported unique to its modulation.
Ubiquitin-mediated protein degradation, Regulation of antiviral signaling via K63-linked ubiquitination, Sensitization to oxidative cell death
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase TRIM4 (TRIM4).